Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tyra Biosciences has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2024.
Tyra Biosciences's investors include RA Capital Management, Cormorant Asset Management, Janus Henderson Investors, Canaan Partners, OrbiMed.
Tyra Biosciences is headquartered in Carlsbad, United States.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tyra Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tyra Biosciences — Funding & Investors." VCBacked, February 2, 2024, https://www.vcbacked.co/company/tyra-biosciences. Accessed July 19, 2026.
VCBacked. (2024). Tyra Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tyra-biosciences
{{cite web |title=Tyra Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/tyra-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated